The study of gender-based differences in the pharmacokinetics (PK) of compounds tested in
animal models has received greater attention in recent years. As early as 1932, the …

Sex and gender influence all aspects of cardiovascular health and disease—including
epidemiology, pathophysiology, diagnosis, clinical manifestation, disease progression, and …

In the last decades, both animal and human studies have neglected female subjects with the
aim of evading a theorized intricacy of feminine hormonal status. However, clinical …

Coronary artery disease (CAD) is a leading cause of mortality and morbidity in most
developed countries. Gender-related differences have been found in the presentation …

Gender differences have been well described in pharmacokinetics and contribute to the
interindividual variation in drug disposition, therapeutic response, and drug toxicity. Sex …

Despite a growing body of evidence, the distinct contributions of biological sex and the
sociocultural dimension of gender to the manifestations and outcomes of ischaemic heart …

Aims Several studies have reported the under‐representation of women in clinical trials,
thereby challenging the external validity of the benefit/risk assessments of launched drugs …

Introduction Racial and ethnic categories are frequently used in pharmacogenetics literature
to stratify patients; however, these categories can be inconsistent across different studies. To …

Physiologic differences between men and women affect drug activity, including
pharmacokinetics and pharmacodynamics. Pharmacokinetics in women is affected by lower …

Background In this paper, we argue for Gender as a Sociocultural Variable (GASV) as a
complement to Sex as a Biological Variable (SABV). Sex (biology) and gender (sociocultural …